Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Mesothelioma: HELP
Articles from Tokyo area
Based on 185 articles published since 2008

These are the 185 published articles about Mesothelioma that originated from Tokyo area during 2008-2019.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8
1 Review Global Asbestos Disaster. 2018

Furuya, Sugio / Chimed-Ochir, Odgerel / Takahashi, Ken / David, Annette / Takala, Jukka. ·Japan Occupational Safety and Health Resource Center; Tokyo 136-0071, Japan. 2009aban@gmail.com. · Department of Environmental Epidemiology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu 807-0804, Japan. odgerel@med.uoeh-u.ac.jp. · Asbestos Diseases Research Institute, University of Sydney, P.O. Box 3628, Rhodes, Sydney, NSW 2138, Australia. ken.takahashi@sydney.edu.au. · Health Partners, LLC, 125 Tun Jose Toves Way, Tamuning 96931, Guam. amdavid@guam.net. · WSH Institute, MOMSC, Singapore, ICOH c/o INAIL, Monteporzio Catone, 00078 Rome, Italy. jstakala@gmail.com. ·Int J Environ Res Public Health · Pubmed #29772681.


2 Review The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. 2017

Marchevsky, Alberto M / LeStang, Nolwenn / Hiroshima, Kenzo / Pelosi, Giuseppe / Attanoos, Richard / Churg, Andrew / Chirieac, Lucian / Dacic, Sanja / Husain, Aliya / Khoor, Andras / Klebe, Sonja / Lantuejoul, Silvie / Roggli, Victor / Vignaud, Jean-Michel / Weynard, Birgit / Sauter, Jennifer / Henderson, Douglas / Nabeshima, Kasuzi / Galateau-Salle, Francoise. ·Department of Pathology Cedars-Sinai Medical Center, Los Angeles, CA. Electronic address: Alberto.Marchevsky@cshs.org. · Department of Pathology, MESOPATH-MESOBANK, Centre León Bérard, Lyon, France. · Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Japan. · Interhospital Pathology Division, Università degli Studi di Milano and IRCCS MultiMedica Group, Milan, Italy. · Department of Pathology University of Wales and Cardiff University, Cardiff, U.K. · Department of Pathology, University of British Columbia, Vancouver, BC. · Department of Pathology, Brigham and Women's Hospital, Boston, MA. · Department of Pathology UPMC-PUH, Pittsburgh, PA. · Department of Pathology, Chicago University, Chicago, IL. · Department of Pathology, Mayo Clinic, Jacksonville, FL. · SA Pathology at Flinders Medical Cemtre, Bedord Park, SA. · Department of Pathology, Centre Hospitalier Universitaire de Grenoble, Grenoble, France. · Department of Pathology Duke University, Durham, NC. · Department of Pathology, CHU de Nancy, Nancy, France. · University Hospital Leuven, Leuven, Belgium. · Department of Pathology Sloan Kettering Memorial Cancer Center, New York, NY. · Department of Pathology Fukuoka University Hospital, Fukuoka, Japan. ·Hum Pathol · Pubmed #28782639.

ABSTRACT: Immunohistochemistry is used to distinguish sarcomatoid malignant mesotheliomas (SMM) from spindle cell and pleomorphic carcinomas (SPC) but there are no guidelines on how to interpret cases that show overlapping or equivocal immunohistochemical findings. A systematic literature review of the immunophenotype of these lesions was performed and the experience with 587 SMM and 46 SPC at MESOPATH was collected. Data were analyzed with Comprehensive Meta-Analysis 2.0 software (Biostat, Englewood, NJ). There were insufficient data to evaluate the differential diagnosis between SPC and localized SMM or peritoneal SMM. Meta-analysis showed considerable overlap in the immunophenotype of these neoplasms and significant data heterogeneity amongst many of the results. Survival data from MESOPATH patients showed no significant differences in overall survival between SMM and SPC patients. Best available evidence was used to formulate several evidence-based guidelines for the differential diagnosis between pleural SMM and SPC. These guidelines emphasize the need to correlate the histopathological findings with clinical and imaging information. Diffuse SMM can be diagnosed with certainty in the presence of malignant spindle cell pleural lesions showing immunoreactivity for cytokeratin and mesothelial markers and negative staining for epithelial markers. Criteria for the interpretation of various other combinations of immunoreactivity for cytokeratin and mesothelial and/or epithelial markers are proposed. Localized sarcomatoid mesotheliomas can only be diagnosed in the presence of spindle cell malignancies that exhibit immunoreactivity for cytokeratin and mesothelial markers and negative immunoreactivity for epithelial lesions, in patients that show no multifocal or diffuse pleural spread and no evidence for extrapleural lesions.

3 Review The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation. 2016

Pass, Harvey / Giroux, Dorothy / Kennedy, Catherine / Ruffini, Enrico / Cangir, Ayten K / Rice, David / Asamura, Hisao / Waller, David / Edwards, John / Weder, Walter / Hoffmann, Hans / van Meerbeeck, Jan P / Nowak, Anna / Rusch, Valerie W / Anonymous19960882. ·Department of Cardiothoracic Surgery, New York University Langone Medical Center, New York, New York. Electronic address: harvey.pass@nyumc.org. · Cancer Research And Biostatistics, Seattle, Washington. · University of Sydney, Putney, New South Wales, Australia. · Thoracic Surgery, University of Turin, Chieri, Italy. · Department of Thoracic Surgery, Ankara University Faculty of Medicine, Ankara, Turkey. · Department of Thoracic Surgery, M. D. Anderson Cancer Center, Houston, Texas. · National Cancer Center, Keio University School of Medicine, Tokyo, Japan. · Glenfield Hospital, Groby Road, Leicestershire, United Kingdom. · Sheffield Teaching Hospital, Department of Cardiothoracic Surgery, Sheffield, United Kingdom. · Division of Thoracic Surgery, University Hospital, Zurich, Switzerland. · Thoraxklinik, University of Heidelberg, Heidelberg, Germany. · Department of Thoracic Oncology, Antwerp University Hospital, Edegem, Belgium. · University of Western Australia, Subiaco, Western Australia, Australia. · Thoracic Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. ·J Thorac Oncol · Pubmed #27670823.

ABSTRACT: For nearly 40 years, there was no generally accepted staging system for malignant pleural mesothelioma. In 1994, members of the International Mesothelioma Interest Group, in collaboration with the International Association for the Study of Lung Cancer, proposed a TNM staging system based on analyses of outcomes in retrospective surgical series and small clinical trials. Subsequently accepted by the American Joint Commission on Cancer and the Union for International Cancer Control for the sixth editions of their staging manuals, this system has since been the international staging standard. However, it has significant limitations, particularly with respect to clinical staging and to the categories for lymph node staging. Here we provide an overview of the development of the International Association for the Study of Lung Cancer malignant pleural mesothelioma staging database, which was designed to address these limitations through the development of a large international data set. Analyses of this database, described in papers linked to this overview, are being used to inform revisions in the eighth editions of the American Joint Commission on Cancer and Union for International Cancer Control staging systems.

4 Review Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review. 2016

Hashimoto, Kana / Okuma, Yusuke / Hosomi, Yukio / Hishima, Tsunekazu. ·Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo, Tokyo, 113-8677, Japan. · Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo, Tokyo, 113-8677, Japan. y-okuma@cick.jp. · Division of Oncology, Research Center for Medical Sciences, Jikei University School of Medicine, Tokyo, Japan. y-okuma@cick.jp. · Department of Pathology, Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan. ·BMC Cancer · Pubmed #27599565.

ABSTRACT: BACKGROUND: Desmoplastic malignant pleural mesothelioma (DMM) is rare histological subtype of diffuse malignant pleural mesothelioma (MPM), accounting for 5-10 % of cases. It has a poor prognosis, with direct invasion of the chest wall or lungs and distant metastases. Its pathological characteristics include dense collagen fibers in a storiform pattern. Its pretreatment pathological diagnosis is difficult, with fibrous pleuritis and reactive mesothelial hyperplasia as potential differential diagnoses. CASE PRESENTATION: We retrospectively reviewed the medical charts of patients with MPM from 1996 to 2012. Among 60 patients with MPM, four patients with the desmoplastic subtype were identified and their clinical characteristics, including asbestos exposure, treatment, and prognosis, were reviewed. All of the patients with DMM were men, with a median age of 69 years (range: 63-74 years). All four patients had been exposed to asbestos. The definitive diagnosis was made histologically and the International Mesothelioma Interest Group classification was advanced (III/IV: 2/3) in all four patients. Three patients were treated with chemotherapy (two with cisplatin/pemetrexed and one with cisplatin/gemcitabine) and one patient underwent surgery. The median survival time in the patients with DMM was 3.8 months (range: 0.9-11.5 months), compared with 10.5 months in patients with other subtypes of MPM in our institution. CONCLUSIONS: DMM continues to have a poor prognosis. It is important to recognize this variant and distinguish it from pleural plaques, non-specific reactive pleural fibrosis, pleurisy, and other lung diseases.

5 Review [Development of New Therapy for Malignant Mesothelioma Based on CD26 Molecule]. 2016

Morimoto, Chikao / Ohnuma, Kei. ·Dept. of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University. ·Gan To Kagaku Ryoho · Pubmed #27431629.

ABSTRACT: CD26 is a 110 kDa, type II transmembrane glycoprotein with dipeptidyl peptidase IV activity and is capable of cleaving Nterminal dipeptides with either L-proline or L-alanine at the penultimate position. Malignant mesothelioma(MM)is an aggressive malignancy arising from the mesothelial cells. It is generally associated with a history of asbestos exposure and has a very poor prognosis. Due to lack of efficacy of conventional treatments, novel therapeutic strategies are urgently needed to improve outcomes. Recently we showed that CD26 is preferentially expressed on epithelial type of MM cells but not on normal mesothelial cells. We have developed a highly biological active humanized anti-CD26 monoclonal antibody(mAb)and have published previously extensive in vivo data demonstrating the anti-tumor activity of humanized anti-CD26 mAb(YS110)in mouse xenograft models. The use of a humanized anti-CD26 mAb may therefore be a rational therapy for patients with MM. The first-in-human(FIH)phase I study performed in France demonstrates that humanized anti-CD26 therapy is generally well-tolerated with preliminary evidence of activity in patients with advanced/refractory CD26-expressing cancers, particularly refractory malignant mesothelioma. From the above results, the phase I clinical trial for malignant mesothelioma in Japan is to be started in the very near future.

6 Review Use of p16 FISH for differential diagnosis of mesothelioma in smear preparations. 2016

Nabeshima, Kazuki / Matsumoto, Shinji / Hamasaki, Makoto / Hida, Tomoyuki / Kamei, Toshiaki / Hiroshima, Kenzo / Tsujimura, Tohru / Kawahara, Kunimitsu. ·Department of Pathology, Fukuoka University Hospital and School of Medicine, Fukuoka, Japan. · Department of Pathology, PCL Japan Fukuoka, Pathology-Cytology Center, Fukuoka, Japan. · Department of Pathology, Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Japan. · Department of Pathology, Hyogo College of Medicine, Hyogo, Japan. · Department of Pathology, Osaka Prefectural Medical Center for Respiratory and Allergic Disease, Habikino, Japan. ·Diagn Cytopathol · Pubmed #27219841.

ABSTRACT: Because most of malignant pleural mesothelioma (MPM) patients first present with pleural effusion, detection of mesothelioma cells on effusion smears is critical for early diagnosis. Recently, accumulating evidence indicating that the cytological diagnosis of MPM supported by ancillary techniques is as reliable as that based on histopathology has led to new guidelines for the cytopathologic diagnosis of MPM. Based on the guidelines, a combination of cytomorphological criteria and verification by ancillary techniques is required for the cytologic diagnosis of MPM. Detection of p16 homozygous deletion by fluorescence in situ hybridization (FISH) is the most reliable ancillary technique for differentiating MPM from reactive mesothelial cells (RMC) because of its relatively high sensitivity and extremely high specificity. We showed that the p16 deletion status of MPM cells in pleural effusions reflected that of the underlying invasive MPM tissues, indicating the usefulness of p16 FISH in effusion smear cytology for MPM diagnosis. Thus, for differentiating MPM from RMC, we propose to perform p16 FISH as often as possible. A positive p16 homozygous deletion supports the diagnosis of MPM. However, a negative result does not rule out the possibility of MPM. In such cases, a morphological assessment is critical. Therefore, we analyzed the morphological characteristics of p16 deletion-positive mesothelioma cells using a combination of virtual microscopy and p16 FISH, and identified three morphological characteristics useful for the differentiation, including cell-in-cell engulfment with or without hump formation, multinucleate cells, and larger berry-like cell aggregates. Diagn. Cytopathol. 2016;44:774-780. © 2016 Wiley Periodicals, Inc.

7 Review Pleuroscopic punch biopsy using insulated-tip diathermic knife-2 for the diagnosis of desmoplastic malignant mesothelioma. 2013

Masai, Kyohei / Sasada, Shinji / Izumo, Takehiro / Taniyama, Tomoko / Nakamura, Yukiko / Chavez, Christine / Sakurai, Hiroyuki / Tsuta, Koji / Tsuchida, Takaaki. ·*Department of Endoscopy, Respiratory Endoscopy Division Departments of †Thoracic Surgery ‡Pathology and Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan. ·J Bronchology Interv Pulmonol · Pubmed #24162121.

ABSTRACT: Desmoplastic malignant mesothelioma (DMM) is a rare subtype of malignant pleural mesothelioma (MPM) and is often difficult to distinguish from pleural fibrosis and reactive mesothelial hyperplasia, especially if the biopsy samples are small. We performed full-thickness pleural biopsy on a lesion suspected to be DMM using an insulated-tip diathermic knife-2 (IT knife-2) during flex-rigid pleuroscopy. IT knife-2 is a novel electrosurgical device for endoscopic submucosal dissection in the early gastrointestinal cancer. It consists of a needle knife with 3 short blades at the distal end attached to an insulated ceramic tip. A 54-year-old man presenting with chest wall mass and thickened pleura, in whom a computed tomography-guided percutaneous needle aspiration had remained negative, underwent flex-rigid pleuroscopy for definitive diagnosis. While applying electric current, we used the IT knife-2 to incise the pleura in a circular shape just above the endothoracic fascia. The incised pleura was removed by forceps and examined pathologically. The microscopic examination was compatible with DMM. We discovered that pleuroscopic punch biopsy using IT knife-2 can diagnose DMM. Use of IT knife-2 during flex-rigid pleuroscopy can obtain sufficient samples from densely thickened pleura, which is difficult to diagnose with small biopsies.

8 Review Surgery for primary intrapericardial tumors in adults. 2013

Taguchi, Shinichi / Yozu, Ryohei. ·Department of Cardiovascular Surgery, Keio University Hospital, Tokyo, Japan. ·J Card Surg · Pubmed #23808619.

ABSTRACT: Primary intrapericardial tumors in adults, whether benign or malignant are rare. Surgical treatment for these tumors are reviewed together with their incidence, classification, clinical features, and diagnosis.

9 Review A potential therapeutic strategy for malignant mesothelioma with gene medicine. 2013

Tada, Yuji / Shimada, Hideaki / Hiroshima, Kenzo / Tagawa, Masatoshi. ·Department of Respirology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan. ·Biomed Res Int · Pubmed #23484132.

ABSTRACT: Malignant mesothelioma, closely linked with occupational asbestos exposure, is relatively rare in the frequency, but the patient numbers are going to increase in the next few decades all over the world. The current treatment modalities are not effective in terms of the overall survival and the quality of life. Mesothelioma mainly develops in the thoracic cavity and infrequently metastasizes to extrapleural organs. A local treatment can thereby be beneficial to the patients, and gene therapy with an intrapleural administration of vectors is one of the potential therapeutics. Preclinical studies demonstrated the efficacy of gene medicine for mesothelioma, and clinical trials with adenovirus vectors showed the safety of an intrapleural injection and a possible involvement of antitumor immune responses. Nevertheless, low transduction efficiency remains the main hurdle that hinders further clinical applications. Moreover, rapid generation of antivector antibody also inhibits transgene expressions. In this paper, we review the current status of preclinical and clinical gene therapy for malignant mesothelioma and discuss potential clinical directions of gene medicine in terms of a combinatory use with anticancer agents and with immunotherapy.

10 Review Gene therapy for malignant mesothelioma: current prospects and challenges. 2013

Tagawa, M / Tada, Y / Shimada, H / Hiroshima, K. ·Division of Pathology and Cell Therapy, Chiba Cancer Center Research Institute, Chiba, Japan. mtagawa@chiba-cc.jp ·Cancer Gene Ther · Pubmed #23392201.

ABSTRACT: Malignant mesothelioma, developed in the thoracic cavity, is resistant to current treatments. Suppression of the local tumor growth is beneficial to the patients since mesothelioma infrequently metastasizes to extrapleural organs. A majority of the tumors have a homologous genetic deletion at the INK4A/ARF locus that includes the p14ARF and the p16INK4A genes, and the genetic defect results in an inactivation of the p53-mediated pathways and in progression of cell cycle through pRb phosphorylation. Preclinical studies targeting the genetic abnormality with adenoviruses showed that restoration of the p53 pathways induced pRb dephosphorylation and subsequently produced anti-tumor effects. A number of preclinical studies with different genes and vector systems demonstrated the therapeutic efficacy and raised the possibility of gene therapy in clinical settings. An intrapleural administration of vectors has several advantages in transducing pleural mesothelioma but activates rapid antibody production which impedes further gene expression. There have been several clinical studies conducted for mesothelioma and these trials showed the feasibility of intrapleural administrations of adenovirus vectors. In this review we summarize major preclinical and clinical gene therapy for mesothelioma, and discuss the advantages of gene therapy in the context of stimulating host immune systems. Accumulating clinical data suggest that an intrapleural administration of viral vectors has distinct aspects which are not observed in other administration routes.

11 Review [Antibody therapy for malignant mesothelioma: humanized anti-cD26 mAb therapy]. 2012

Morimoto, Chikao / Ohnuma, Kei. ·Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University. ·Nihon Rinsho · Pubmed #23259393.

ABSTRACT: Malignant mesothelioma (MM) is an aggressive malignancy arising from the mesothelial cells. It is generally associated with a history of asbestos exposure and has a very poor prognosis. Due to lack of efficacy of conventional treatments, novel therapeutic strategies are urgently needed to improve outcomes. Recently we showed that CD26 is preferentially expressed on epithelial type of MM cells but not on normal mesothelial cells. We have developed a highly biological active humanized anti-CD26 mAb and this antibody inhibited growth and invasion of MM cells and induced long-term survival of tumor transplanted SCID mice. It is conceivable that CD26 is a new therapeutic target for MM. Phase I/II clinical trial for MM has been already starting in France and we plan to start the clinical trial for MM as soon as possible in Japan.

12 Review Year in review 2011: acute lung injury, interstitial lung diseases, physiology, sleep and lung cancer. 2012

Takahashi, Kazuhisa / Eves, Neil D / Piper, Amanda / Song, Yuanlin / Maher, Toby M. ·Department of Respiratory Medicine, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan. ·Respirology · Pubmed #22248252.

ABSTRACT: -- No abstract --

13 Review Malignant pleural mesothelioma presenting as an acute surgical abdomen due to metastatic jejunal perforation. 2010

Gocho, Kyoko / Isobe, Kazutoshi / Kaburaki, Kyohei / Honda, Yoshiko / Mitsuda, Aki / Akasaka, Yoshikiyo / Shimada, Nagato / Takagi, Keigo / Homma, Sakae. ·Department of Respiratory Medicine, Toho University Omori Medical Center, Tokyo. ·Intern Med · Pubmed #20228599.

ABSTRACT: A 52-year-old man was admitted to our hospital in June 2008 presenting abnormal tumor lesions along the left pleura on chest X-ray. The needle-biopsied specimen of the left pleura proved the biphasic type of malignant mesothelioma. However, he complained of acute abdominal pain 7 days after the diagnosis. Chest X-ray revealed free air below the right diaphragm. Emergency surgery revealed a 4-cm perforating jejunal tumor with peritonitis. Histopathology of the resected jejunum demonstrated a metastatic tumor of malignant pleural mesothelioma. This is the first reported case of malignant pleural mesothelioma presenting as an acute surgical abdomen due to jejunal metastasis with perforation.

14 Review [Intrapleural perfusion hyperthermo-chemotherapy with cisplatin in patients with malignant pleural mesothelioma]. 2009

Sakaguchi, Hirozo / Kaneko, Koichi. ·Department of General Thoracic Surgery, Saitama Medical University International Medical Center, Saitama, Japan. ·Nihon Geka Gakkai Zasshi · Pubmed #19999570.

ABSTRACT: The preferred treatment for patients with malignant pleural mesothelioma (MPM) has not been determined. In order to obtain adequate control of malignant effusion for multimodality therapy, we have introduced intrapleural perfusion hyperthermo-chemotherapy (IPHC) with cisplatin. IPHC was performed with a roller pump and heat exchanger. Cisplatin was added when the temperature stabilized to a mean of 42.5 degrees C. Dosages of cisplatin were 80 mg/m2. The circuit was filled with 2,000 ml saline. A IPHC was performed for 60 minutes under both lung ventilation. IPHC with cisplatin is feasible, easy to perform, and relatively safe. This method had brought an ideal pleural adhesion. IPHC may offer excellent local control for patients with MPM. Some literatures have reported the utility of IPHC for trimodality therapy on MPM.

15 Review [What is the role of pleuropneumonectomy in malignant pleural mesothelioma?]. 2009

Takagi, Keigo. ·Department of Chest Surgery, Toho University Omori Medical Center, Tokyo, Japan. ·Nihon Geka Gakkai Zasshi · Pubmed #19999569.

ABSTRACT: In this report, the results of conventional pleuropneumonectomy in malignant diffuse mesothelioma are reviewed, and the role of this aggressive surgery in multidisciplinary treatment is discussed. The surgical results may improve owing to recent advances in medical technology, although the postoperative survival time after pleuropneumonectomy has remained nearly the same for the past 40 years. The problems with pleuropneumonectomy are high mortality and morbidity rates, high local recurrence rates, and almost the same survival rates as seen after pleurectomy. The indications for this aggressive surgery are limited to stage I, II, and III disease based on an accurate staging system, with induction therapy for macroscopic radical resection and postoperative chemoradiation therapy. In addition, patients must be monitored for the development of major complications perioperatively. The natural history of this disease should be clarified to determine the effectiveness of various forms of therapy. Precise analysis of the accumulated data from many institutions will help to improve the results of pleuropneumonectomy.

16 Review Microstructures and biological influence of environmental exposure of asbestos. 2009

Yada, Keiji / Kohyama, Norihiko. ·Tohken Co., Ltd, Tokyo, Japan. kyada@tohken.co.jp ·Biomed Mater Eng · Pubmed #19581718.

ABSTRACT: Asbestos minerals are thin fiber type of minerals and honorably said as "the minerals of the miracle" because of their valuable natures even in the strategic field. On the other hand, the relation between asbestos exposure and diseases such as lung cancer and malignant mesothelioma was proved around 1970 by epidemiology and an animal experiment in relation to their microstructures. Here, microstructures of chrysotile asbestos, a mainstream of asbestos substances, are shown. It is also shown that in what kinds of environment people are exposed to asbestos and what kinds of biological or epidemical things happen after asbestos exposure. Many kinds of fibrous materials as the substitutes of asbestos are described in relation to their carcinogenicity.

17 Review Gene therapy for malignant pleural mesothelioma: present and future. 2008

Tada, Yuji / Takiguchi, Yuichi / Hiroshima, Kenzo / Shimada, Hideaki / Ueyama, Taro / Nakamura, Makoto / Tatsumi, Koichiro / Kuriyama, Takayuki / Tagawa, Masatoshi. ·Department of Respirology, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan. ·Oncol Res · Pubmed #19192718.

ABSTRACT: Malignant pleural mesothelioma is relatively rare in frequency but one of the intractable diseases linked with asbestos exposure. Clinical outcomes with the present treatment modalities are unsatisfactory and no effective prevention method has been reported. Growing numbers of the patients in the Western countries with a long latent period need development of a novel therapeutic strategy. Gene therapy is a candidate for mesothelioma treatment because of its easy accessibility of a vector-mediated gene medicine into the intrapleural cavity. Several preclinical studies demonstrated that the gene medicine produced antitumor effects, suggesting the feasibility in clinical settings. In this article, we review the current status of gene therapy and clinical trials targeting mesothelioma and address possible directions to improve the efficacy.

18 Review [Case of malignant mesothelioma presenting as a perineal and intrascrotal mass]. 2008

Washino, Satoshi / Terauchi, Fumihito / Matsuzaki, Atsushi / Kobayashi, Yutaka. ·Department of Urology, Jichi Saitama Medical Center. ·Hinyokika Kiyo · Pubmed #18975578.

ABSTRACT: We report here a case of malignant mesothelioma presenting as a perineal and intrascrotal mass. A 42-year-old Japanese male presented with an enlarging mass in the perineum and intrascrotum. Although the initial clinical diagnosis was perineal abscess, angiography revealed a tumor in the perineum and intrascrotum. The tumor was resected, and the pathological examination revealed malignant mesothelioma. Two months after the operation, a hard irregular mass with severe hemorrhage was noticed in the perineum, and was resected. A few weeks after the second operation local recurrence and, inguinal and intrapelvic retroperitoneal lymphadenopathy were found. Radiotherapy to recurrent sites was not effective. The patient died six months after the initiation of therapy. To our knowledge, 24 cases of malignant mesothelioma in the perineum or intrascrotum were reported in Japan and this case was thought to be the 25th case in Japan.

19 Review Pleuropneumonectomy: an effective treatment modality for malignant pleural mesothelioma? 2008

Takagi, Keigo. ·Department of Chest Surgery, Toho University Omori Medical Center, Tokyo, Japan. ·Ann Thorac Cardiovasc Surg · Pubmed #18577890.

ABSTRACT: -- No abstract --

20 Clinical Trial First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers. 2017

Angevin, Eric / Isambert, Nicolas / Trillet-Lenoir, Véronique / You, Benoit / Alexandre, Jérôme / Zalcman, Gérard / Vielh, Philippe / Farace, Françoise / Valleix, Fanny / Podoll, Thomas / Kuramochi, Yu / Miyashita, Itaru / Hosono, Osamu / Dang, Nam H / Ohnuma, Kei / Yamada, Taketo / Kaneko, Yutaro / Morimoto, Chikao. ·Gustave Roussy, Université Paris-Saclay, Drug Development Department (DITEP), Villejuif, France. · Centre Georges-François Leclerc, Unité de Phases Précoces, Dijon, France. · Institut de Cancérologie des Hospices Civils de Lyon, CITOHL, Lyon, France. · Hôpital Cochin, Paris, France. · Centre Hospitalier Universitaire (CHU) de Caen, Centre de Recherche Clinique/Essais de phases précoces, Caen, France. · Gustave Roussy, Translational Research Laboratory, Villejuif, France. · FV Clinical subcontractor for SynteractHCR SAS, Levallois-Perret, France. · Y's therapeutics Inc., Redwood City, CA, USA. · Kissei Pharmaceutical Co., Ltd, Tokyo, Japan. · Department of Rheumatology and Allergy, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. · Division of Hematology/Oncology, University of Florida, Gainesville, FL, USA. · Department of Therapy Development and Innovation for Immune Disorders and Cancers, Graduate School of Medicine, Juntendo University, Tokyo, Japan. · Keio University School of Medicine, Tokyo, Japan. · Saitama Medical University, Saitama, Japan. · Y's AC Co., Ltd, Tokyo, Japan. ·Br J Cancer · Pubmed #28291776.

ABSTRACT: BACKGROUND: YS110 is a humanised IgG1 monoclonal antibody with high affinity to the CD26 antigen. YS110 demonstrated preclinical anti-tumour effects without significant side effects. METHODS: This FIH study was designed to determine the maximal tolerated dose (MTD) and recommended phase 2 dose (RP2D) to assess the tolerance, pharmacokinetics (PK) and pharmacodynamics profiles of YS110 and preliminary efficacy. YS110 were initially administered intravenously once every 2 weeks (Q2W) for three doses and then, based on PK data, once every week (Q1W) for five doses in patients with CD26-expressing solid tumours. RESULTS: Thirty-three patients (22 mesothelioma) received a median of 3 (range 1-30) YS110 infusions across six dose levels (0.1-6 mg kg CONCLUSIONS: YS110 is well tolerated up to 6 mg kg

21 Clinical Trial Diagnostic Utility of Pleural Fluid Cell Block versus Pleural Biopsy Collected by Flex-Rigid Pleuroscopy for Malignant Pleural Disease: A Single Center Retrospective Analysis. 2016

Miyoshi, Shion / Sasada, Shinji / Izumo, Takehiro / Matsumoto, Yuji / Tsuchida, Takaaki. ·Department of Endoscopy, Respiratory Endoscopy Division, National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan. · Department of Respiratory Medicine, Toho University Omori Medical Center, Ota-Ku, Tokyo, Japan. · Department of Respiratory Medicine, Tokyo Saiseikai Central Hospital, Minato-Ku, Tokyo, Japan. ·PLoS One · Pubmed #27880851.

ABSTRACT: BACKGROUND: Some trials recently demonstrated the benefit of targeted treatment for malignant disease; therefore, adequate tissues are needed to detect the targeted gene. Pleural biopsy using flex-rigid pleuroscopy and pleural effusion cell block analysis are both useful for diagnosis of malignancy and obtaining adequate samples. The purpose of our study was to compare the diagnostic utility between the two methods among patients with malignant pleural disease with effusion. METHODS: Data from patients who underwent flex-rigid pleuroscopy for diagnosis of pleural effusion suspicious for malignancy at the National Cancer Center Hospital, Japan between April 2011 and June 2014 were retrospectively reviewed. All procedures were performed under local anesthesia. At least 150 mL of pleural fluid was collected by pleuroscopy, followed by pleural biopsies from the abnormal site. RESULTS: Thirty-five patients who were finally diagnosed as malignant pleural disease were included in this study. Final diagnoses of malignancy were 24 adenocarcinoma, 1 combined adeno-small cell carcinoma, and 7 malignant pleural mesothelioma (MPM), and 3 metastatic breast cancer. The diagnostic yield was significantly higher by pleural biopsy than by cell block [94.2% (33/35) vs. 71.4% (25/35); p = 0.008]. All patients with positive results on cell block also had positive results on pleural biopsy. Eight patients with negative results on cell block had positive results on pleural biopsy (lung adenocarcinoma in 4, sarcomatoid MPM in 3, and metastatic breast cancer in 1). Two patients with negative results on both cell block and pleural biopsy were diagnosed was sarcomatoid MPM by computed tomography-guided needle biopsy and epithelioid MPM by autopsy. CONCLUSION: Pleural biopsy using flex-rigid pleuroscopy was efficient in the diagnosis of malignant pleural diseases. Flex-rigid pleuroscopy with pleural biopsy and pleural effusion cell block analysis should be considered as the initial diagnostic approach for malignant pleural diseases presenting with effusion.

22 Clinical Trial Trimodality strategy for treating malignant pleural mesothelioma: results of a feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation (Japan Mesothelioma Interest Group 0601 Trial). 2016

Hasegawa, Seiki / Okada, Morihito / Tanaka, Fumihiro / Yamanaka, Takeharu / Soejima, Toshinori / Kamikonya, Norihiko / Tsujimura, Tohru / Fukuoka, Kazuya / Yokoi, Kohei / Nakano, Takashi. ·Department of Thoracic Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan. hasegawa@hyo-med.ac.jp. · Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan. · Department of Surgery, University of Occupational and Environmental Health, Kitakyusyu, Japan. · Department of Biostatistics, Yokohama City University, Yokohama, Japan. · Department of Radiation Oncology, Hyogo Cancer Center, Akashi, Japan. · Department of Radiation Oncology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan. · Department of Pathology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan. · Department of Medical Oncology, Sakai Hospital, Kinki University Faculty of Medicine, Osaka, Japan. · Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. · Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan. ·Int J Clin Oncol · Pubmed #26577445.

ABSTRACT: PURPOSE: We conducted a prospective multi-institutional study to determine the feasibility of trimodality therapy (TMT) comprising induction chemotherapy followed by extrapleural pneumonectomy (EPP) and radiation therapy in Japanese patients with malignant pleural mesothelioma (MPM). METHODS: Major eligibility criteria were histologically confirmed diagnosis of MPM, including clinical subtypes T0-3, N0-2, M0 disease; no prior treatment for the disease; age 20-75 years; Eastern Cooperative Oncology Group performance status 0 or 1; predicted postoperative forced expiratory volume >1000 ml in 1 s; written informed consent. Treatment methods comprised induction chemotherapy using pemetrexed (500 mg/m(2)) plus cisplatin (60 mg/m(2)) for three cycles, followed by EPP and postoperative hemithoracic radiation therapy (54 Gy). Primary endpoints were macroscopic complete resection (MCR) rate for EPP and treatment-related mortality for TMT. RESULTS: Forty-two eligible patients were enrolled: median age 64.5 (range 43-74) years; M:F = 39:3, clinical stage I:II:III = 14:13:15; histological type epithelioid were sarcomatoid; biphasic; others = 28:1:9:4. Of 42 patients, 30 completed EPP with MCR and 17 completed TMT. The trial met the primary endpoints, with an MCR rate of 71 % (30/42) and treatment-related mortality of 9.5 % (4/42). Overall median survival time and 2-year survival rate for 42 registered patients were 19.9 months and 42.9 %, respectively. Two-year relapse-free survival rate of 30 patients who completed EPP with MCR was 37.0 %. CONCLUSION: This phase II study met the predefined primary endpoints, but its risk/benefit ratio was not satisfactory.

23 Clinical Trial Specific expression of human intelectin-1 in malignant pleural mesothelioma and gastrointestinal goblet cells. 2012

Washimi, Kota / Yokose, Tomoyuki / Yamashita, Makiko / Kageyama, Taihei / Suzuki, Katsuo / Yoshihara, Mitsuyo / Miyagi, Yohei / Hayashi, Hiroyuki / Tsuji, Shoutaro. ·Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan. ·PLoS One · Pubmed #22768319.

ABSTRACT: Malignant pleural mesothelioma (MPM) is a fatal tumor. It is often hard to discriminate MPM from metastatic tumors of other types because currently, there are no reliable immunopathological markers for MPM. MPM is differentially diagnosed by some immunohistochemical tests on pathology specimens. In the present study, we investigated the expression of intelectin-1, a new mesothelioma marker, in normal tissues in the whole body and in many cancers, including MPM, by immunohistochemical analysis. We found that in normal tissues, human intelectin-1 was mainly secreted from gastrointestinal goblet cells along with mucus into the intestinal lumen, and it was also expressed, to a lesser extent, in mesothelial cells and urinary epithelial cells. Eighty-eight percent of epithelioid-type MPMs expressed intelectin-1, whereas sarcomatoid-type MPMs, biphasic MPMs, and poorly differentiated MPMs were rarely positive for intelectin-1. Intelectin-1 was not expressed in other cancers, except in mucus-producing adenocarcinoma. These results suggest that intelectin-1 is a better marker for epithelioid-type MPM than other mesothelioma markers because of its specificity and the simplicity of pathological assessment. Pleural intelectin-1 could be a useful diagnostic marker for MPM with applications in histopathological identification of MPM.

24 Article A novel diagnostic method for distinguishing parapneumonic effusion and empyema from other diseases by using the pleural lactate dehydrogenase to adenosine deaminase ratio and carcinoembryonic antigen levels. 2019

Saraya, Takeshi / Ohkuma, Kosuke / Koide, Takashi / Goto, Hajime / Takizawa, Hajime / Light, Richard W. ·Kyorin University School of Medicine, Department of Respiratory Medicine, Mitaka City, Tokyo. · Respiratory Disease Center, Fukujuji Hospital, Japan Anti-Tuberculosis Association, Kiyose, Japan. · Division of Allergy/Pulmonary/Critical Care, Vanderbilt University Medical Center, Nashville, Tennessee. ·Medicine (Baltimore) · Pubmed #30921217.

ABSTRACT: Pleural effusions are a common medical problem not only for pulmonologists but also for general physicians, often needing thoracentesis for a definite diagnosis. However, thoracentesis cannot always reveal malignant cells or microbiological evidence.In this context, we prospectively enrolled a total of 289 patients with pleural effusions due to diverse etiologies: parapneumonic effusion (PPE) (63), empyema (22), tuberculous pleural effusion (TBPE) (54), malignant pleural effusion (MPE) (140), or chronic renal failure (CRF)/congestive heart failure (CHF) (10). The MPE group consisted of lung cancer (adenocarcinoma, n = 90; squamous cell carcinoma, n = 5; small cell carcinoma, n = 4), malignant lymphoma (n = 17), malignant mesothelioma (n = 11), malignant melanoma (n = 3), and metastasis from other organs (n = 10).This study demonstrated that the pleural lactate dehydrogenase (LDH)to adenosine deaminase (ADA) ratios differed significantly between patients with CHF/CRF, MPE, TBPE, empyema, and PPE. We discovered a simple method to differentiate pleural diseases based on the pleural LDH to ADA ratio and carcinoembryonic antigen (CEA). A pleural LDH to ADA ratio greater than 15.5 and a pleural CEA level of less than 5 ng/mL is indicative of PPE or empyema rather than TBPE, MPE, or transudative pleural effusion (CRF, CHF).This method has a sensitivity of 62.0%, a specificity of 91.0%, and an area under the receiver operating characteristic curve of 0.765 (95% confidence interval [CI]: 0678-0.852, P < .001), odds ratio of 16.6 (95% CI: 7.28-37.8, P < .001), a positive likelihood ratio (LR) of 6.8, and a negative LR of 0.02.

25 Article Tenascin XB Is a Novel Diagnostic Marker for Malignant Mesothelioma. 2019

Nakayama, Koji / Seike, Masahiro / Noro, Rintaro / Takeuchi, Susumu / Matsuda, Kuniko / Kunugi, Shinobu / Kubota, Kaoru / Gemma, Akihiko. ·Division of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. · Division of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan mseike@nms.ac.jp. · Division of Pathology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. ·Anticancer Res · Pubmed #30711938.

ABSTRACT: BACKGROUND/AIM: Malignant mesothelioma (MM) is an aggressive tumor with poor prognosis. The establishment of a new diagnostic and therapeutic approach for MM is expected. This study investigated the diagnostic significance of tenascin XB (TNXB) for MM. MATERIALS AND METHODS: TNXB gene expression was found to be significantly higher in MM tumor tissues compared to paired normal tissues, as assessed by the Gene Expression Omnibus database. The inhibition of TNXB using small interfering RNAs suppressed the proliferation and colony formation of MM cells. Expression of TNXB and calretinin, a current diagnostic marker of MM, was evaluated by immunohistochemistry. RESULTS: The sensitivity and specificity of TNXB for MM were 80.0% and 69.5%, respectively. When the detection of TNXB was combined with that of calretinin, 83.3% of MM cases were detected. CONCLUSION: These findings suggest that TNXB is a novel diagnostic biomarker for MM. A combination of detecting TNXB and calretinin may be useful for the differential diagnosis of MM from lung adenocarcinoma.